Welcome to our dedicated page for Sutro Biopharma news (Ticker: STRO), a resource for investors and traders seeking the latest updates and insights on Sutro Biopharma stock.
Sutro Biopharma, Inc. (NASDAQ: STRO) is a clinical-stage biopharmaceutical company based in South San Francisco, focused on the discovery, development, and manufacturing of next-generation cancer therapeutics. The company leverages its proprietary cell-free protein synthesis platform, XpressCF®, to produce novel antibody-drug conjugates (ADCs) and bispecific antibodies that target cancer cells with precision, aiming to offer improved safety and efficacy over traditional treatments.
Key products in Sutro's pipeline include STRO-001, designed for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002 (also known as luveltamab tazevibulin or 'luvelta') for the treatment of ovarian and endometrial cancers. The company has recently initiated Phase 2/3 clinical trials for luvelta in platinum-resistant ovarian cancer (PROC) and is progressing towards trials for endometrial cancer. Sutro is also exploring additional indications, including non-small cell lung cancer and a rare pediatric form of acute myeloid leukemia (AML).
Recent achievements include the appointment of Dr. Hans-Peter Gerber as Chief Scientific Officer and the presentation of promising preliminary data for luvelta in endometrial cancer at ESMO 2023. Financially, Sutro reported cash and investments totaling $321.1 million and an additional $34.0 million in Vaxcyte common stock as of September 30, 2023, providing a projected cash runway into the first half of 2025.
Sutro's innovative approach is not limited to its product pipeline. The company operates the world's only cGMP cell-free manufacturing facility in San Carlos, California, giving it a strategic advantage in the biopharmaceutical industry. Sutro's numerous partnerships and collaborations have generated about $785 million in payments through September 2023, reflecting the significant value of its platform.
Sutro continues to build a robust pipeline and high-value collaborations, including recent partnerships with healthcare-focused institutional investors. The company has a strong financial outlook and a growing portfolio of clinical-stage candidates aimed at transforming cancer treatment. For more information, visit Sutro Biopharma.
Sutro Biopharma (NASDAQ: STRO) announced on April 26, 2022, that it granted 155,000 stock options and 18,000 Restricted Stock Units (RSUs) to two new employees. These inducement grants, made per Nasdaq Listing Rule 5635(c)(4), aim to attract talent. The RSUs vest over four years, while stock options vest similarly but monthly after the first year. Sutro, a clinical-stage company, leverages its proprietary platforms to develop next-generation cancer therapeutics like STRO-001 and STRO-002, which have received FDA designations for their clinical trials.
Sutro Biopharma, Inc. (NASDAQ: STRO) announced new nonclinical data on its folate receptor alpha-targeting antibody-drug conjugate STRO-002 at the AACR Annual Meeting 2022. Currently in Phase 1 clinical trials for ovarian and endometrial cancers, STRO-002 demonstrated significant anti-tumor immunity through in vitro studies inducing immunogenic cell death. In vivo studies revealed enhanced efficacy in combination with checkpoint inhibitors and anti-VEGF antibodies. The data highlights STRO-002's potential for targeting FolRα-expressing tumors and its promising role in non-small cell lung cancer.
Sutro Biopharma (NASDAQ: STRO) announced that CEO Bill Newell will present at the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 3:00 p.m. ET. The presentation will be available on the company's website. Sutro focuses on next-generation cancer therapeutics through protein engineering. It has developed STRO-001 and STRO-002, targeting advanced B-cell malignancies and ovarian/endometrial cancers, respectively. Both candidates have received FDA designations to expedite development. Sutro is committed to transforming cancer treatment by creating medicines for unmet medical needs.
Sutro Biopharma (NASDAQ: STRO) announced advancements in its novel immunostimulatory antibody-drug conjugate (iADC) modality at the 12th Annual World ADC conference held in London from March 29 to April 1, 2022. This innovative approach uses a dual mechanism to target tumors, leveraging a cytotoxic warhead and a toll-like receptor (TLR) agonist to activate the immune system. Presentations featured data on STRO-002, aimed at treating ovarian and endometrial cancers, which has received Fast Track designation from the FDA. Sutro aims to develop therapies that address unmet needs in oncology.
Sutro Biopharma (NASDAQ: STRO) announced that CEO Bill Newell will participate in the Ovarian Cancer Panel at the Cowen 42nd Annual Healthcare Conference on March 9, 2022, at 12:50 p.m. ET. A live webcast can be accessed on the company's website, with a replay available for 30 days. Sutro is focused on cancer therapeutics through its platforms XpressCF® and XpressCF+™, which led to drug candidates like STRO-001 and STRO-002, both in clinical trials with FDA designations. Sutro is dedicated to improving cancer treatment for patients.
Sutro Biopharma (STRO) reported a strong performance for 2021, with revenue increasing to $61.9 million from $42.7 million in 2020, driven by collaborations with Merck, BMS, and EMD Serono. The company is advancing its lead candidate, STRO-002, which targets ovarian cancer, completing its Phase 1 trial enrollment and planning a registrational path forward. However, operating expenses rose to $160.4 million, up from $113.8 million, partly due to stock-based compensation. Sutro's cash reserves stood at $229.5 million, providing runway into late 2023.
Sutro Biopharma (NASDAQ: STRO), a clinical-stage company based in South San Francisco, announced that CEO Bill Newell will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 11:15 a.m. ET. The live presentation will be available via webcast on the company's website. Sutro focuses on advanced oncology therapeutics, using its XpressCF® platform to develop candidates like STRO-001 and STRO-002, currently in clinical trials for B-cell malignancies and ovarian cancer, respectively.
Sutro Biopharma (NASDAQ: STRO) announced interim results from its Phase 1 study of STRO-002, a folate receptor alpha-targeting ADC for advanced ovarian cancer. The study, involving 44 patients with extensive prior treatments, reported an overall response rate (ORR) of 33%. Notably, patients starting at a 5.2 mg/kg dose level exhibited a 47% ORR. Encouraging safety signals included no new complications. Sutro plans to advance STRO-002 into further clinical phases, leveraging its Fast Track designation.
Sutro Biopharma (NASDAQ: STRO) has entered an exclusive license agreement with Tasly Biopharmaceuticals for the development and commercialization of STRO-002 in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan. Sutro will receive an upfront payment of $40 million and could earn up to $345 million in milestone payments. STRO-002 is currently in clinical trials for ovarian and endometrial cancers. Sutro retains rights outside of Greater China and will receive royalties based on STRO-002's net sales.
Sutro Biopharma (STRO) announced a KOL virtual event on Jan. 5, 2022, to share interim data from the Phase 1 study of STRO-002, an antibody-drug conjugate for advanced ovarian cancer. The trial, which enrolled 44 patients by Nov. 2021, aims to assess the efficacy, safety, and tolerability of STRO-002 in patients who have undergone multiple prior therapies. The event will feature presentations from Sutro management and Dr. R. Wendel Naumann from the Levine Cancer Institute.
FAQ
What is the current stock price of Sutro Biopharma (STRO)?
What is the market cap of Sutro Biopharma (STRO)?
What is Sutro Biopharma's focus?
What are Sutro Biopharma's key products?
What recent achievements has Sutro Biopharma accomplished?
What is Sutro Biopharma's financial outlook?
Where is Sutro Biopharma headquartered?
What is unique about Sutro Biopharma's manufacturing capabilities?
What collaborations has Sutro Biopharma recently entered into?
What are the upcoming milestones for Sutro Biopharma?
How can I learn more about Sutro Biopharma?
Who should I contact for more information about Sutro Biopharma?
